Psychiatric and cognitive function in patients with Neuroendocrine tumours with carcinoid syndrome.

Psychiatric and cognitive function in patients with Neuroendocrine tumours with carcinoid syndrome. - Psychiatric and cognitive function in patients with NET.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45631

Enrollment

Registered

2017-05-17

Start date

2017-07-10

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitieve stoornissen cognitive impairment depression

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with ileal NET with metastatic disease, diagnosed between 2012 and 2017 - Signed informed consent

Exclusion criteria

Exclusion criteria: - No sufficient understanding of the Dutch language. - A previous cerebro vascular accident (assessed through review of the chart and checked with the patient) - Severe cognitive problems such as a dementia. - Delirium in the past 3 months - Use of 5-HT modulating medication, such as SSRIs or SNRIs, or tryptophan - Current chemotherapy, or chemotherapy in the past 5 years - Previous malignancy in the past 5 years, except for adequately treated basal cell carcinoma of the skin. - Life expectancy shorter than 3 months - Patients with a primary psychotic disorder (schizophrenia)

Design outcomes

Primary

Measure	Time frame
To assess the severity of cognitive dysfunction and depressive symptoms in ileal NET patients and to relate this to peripheral 5-HT production.	—

Secondary

Measure	Time frame
- To assess the prevalence of formal psychiatric diagnoses (depressive disorder, anxiety disorder) in patients with metastatic ileal NET and relate this to peripheral 5-HT production - To assess the severity of irritability and anger in patients with metastatic ileal NET and to relate this to peripheral 5-HT production. - To identify subgroups of patients with metastatic ileal NET that are more vulnerable for depressive symptoms (e.g. with a (family) history of depression or a polymorphism in serotonin transporter genes). - To assess the prevalence of cognitive problems on specific domains in patients with metastatic ileal NET and relate this to peripheral 5-HT production. - To assess the emotional bias in NET patients and to relate this to 5-HT production, depressive symptoms and irritability - To assess the association between psychiatric symptoms and cognitive impairment and peripheral 5-HT production. - To assess the quality of life of the patients and to relate this to peripheral 5-HT	—

Measure

Time frame

- To assess the prevalence of formal psychiatric diagnoses (depressive disorder, anxiety disorder) in patients with metastatic ileal NET and relate this to peripheral 5-HT production - To assess the severity of irritability and anger in patients with metastatic ileal NET and to relate this to peripheral 5-HT production. - To identify subgroups of patients with metastatic ileal NET that are more vulnerable for depressive symptoms (e.g. with a (family) history of depression or a polymorphism in serotonin transporter genes). - To assess the prevalence of cognitive problems on specific domains in patients with metastatic ileal NET and relate this to peripheral 5-HT production. - To assess the emotional bias in NET patients and to relate this to 5-HT production, depressive symptoms and irritability - To assess the association between psychiatric symptoms and cognitive impairment and peripheral 5-HT production. - To assess the quality of life of the patients and to relate this to peripheral 5-HT

—

Countries

Netherlands

Outcome results